Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · LeMaitre Vascular (LMAT)

LeMaitre Q3 sales rise 11% to $61.0 million; company raises profit guidance

Positive Impact 4 of 5 earnings Written later

LeMaitre Vascular reported preliminary, unaudited third-quarter 2025 results, with sales up 11% to $61.0 million and GAAP diluted EPS up 54% to $0.75. The results include a non-recurring $3.4 million Employee Retention Tax Credit benefit, and excluding it, adjusted diluted EPS was $0.62, up 27%. Management said it increased its bottom-line guidance, with full-year 2025 GAAP diluted EPS now expected at $2.48 to $2.53.

Key points

  • Q3 2025 net sales $61.0 million, up 11% (12% organic); GAAP diluted EPS $0.75, up 54%
  • Adjusted diluted EPS $0.62, up 27%, excluding the Employee Retention Tax Credit benefit
  • Full-year 2025 sales guidance $247 million to $249 million; Q4 2025 sales guidance $61.8 million to $63.8 million
  • Quarterly dividend of $0.20 per share, payable December 4, 2025, to holders of record on November 20, 2025

The filing

CompanyLeMaitre Vascular (LMAT)
Form8-K, current report
Filed with the SECNov 6, 2025, 4:03 PM ET
Accession number0001193125-25-269454

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.